Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Spain

European Research Council grant · Running

LABORIOUS Reliable and scalable procedures for the isolation and loading of extracellular vesicles

Coordinator
Universidad De Zaragoza, Spain
Runs
1 May 2024 to 30 April 2026
Status
Running
EU funding
€150k
Total cost
—
Partners
1 organisations in 1 countries
Type
European Research Council grant
Grant agreement
101158233

What the project is doing

In the project's own words, from its summary on CORDIS.

Exosome-based therapies are among the hottest topics in biomedical research, driven by the unique properties of exosomes regarding stability, low immunogenicity, prolonged circulation and especially, selective targeting. In 2022, over 50 clinical trials using exosomes for therapy were under way, in diseases ranging from cancer to diabetes to central nervous system disorders. However, both current research on exosomes and their future translation into clinical therapies are hindered by two significant problems.

The first is the isolation of exosomes (and of extracellular vesicles in general), a highly challenging task due to: i) the high complexity of the body fluids that contain them, and ii) the delicate nature of exosomes themselves: soft entities of 50-150 nm whose membrane is responsible for key properties and must be preserved. Ultracentrifugation, the standard isolation method, has clear limitations: low yields, impurity of the products and damage to exosomal membranes due to long processing times at high g.

While numerous alternatives have been commercialized (size, affinity and precipitation-based methods), these issues remain unsolved. The second problem relates to the loading of therapeutic agents (nanoparticles, drugs, siRNA, miRNA), into exosomes without damaging their membranes, another challenge without a solution today. LABORIOUS leverages the experience gained in AdG CADENCE to propose innovative solutions. A novel tangential filtration procedure will segregate exosomes by size, removing impurities and minimizing pressure-induced membrane damage.

Also, a pioneering continuous electroporation system will provide unprecedented control, allowing the load of therapeutic cargo with minimal membrane disruption. Results will be closely monitored for patenting and commercialization, in collaboration with an industrial observer.

Topics

Who is involved

OrganisationCityCountryRole
Universidad De ZaragozaZaragozaSpainCoordinator

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI